A cohort study was conducted in a cancer center to identify risk factors for bacteremia with vancomycin-resistant enterococci (VRE) in neutropenic cancer patients colonized with VRE. There were 10 patients with VRE bacteremia among 56 colonized with VRE, of whose charts 51 were available for review. One hundred percent of patients with VRE bacteremia (10 of 10) vs. 56% of patients without VRE bacteremia (23 of 41) had acute leukemia ( P Å .01, Fisher's exact test). Four of the 10 patients with VRE bacteremia had a positive Clostridium difficile toxin assay within 6 days of their first positive VRE blood culture. Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis. When a Cox proportional hazards model was used to account for differences in follow-up time, C. difficile infection was the only statistically significant risk factor (risk ratio, 8.2; P Å .007) for VRE bacteremia in VRE-colonized patients with acute leukemia.
Although the enterococcus is not a highly virulent organism
Greenebaum Cancer Center from January 1992 through June in healthy hosts, it can cause life-threatening infection in immu-1996. The facility is a comprehensive cancer center at the nosuppressed patients, including those with cancer. NeutroUniversity of Maryland Hospital that provides both inpatient penic cancer patients are at high risk for bacteremia with organand outpatient care for patients with acute leukemia, other isms that originate from their gastrointestinal tract. Other hematologic malignancies, and solid tumors. Neutropenic painvestigators have shown that gastrointestinal colonization with tients (neutrophil count, õ1 1 10 9 /L) with temperatures of vancomycin-resistant enterococci (VRE) is a risk factor for ú100.4ЊF and/or signs of infection are admitted to the hospital bacteremia with VRE in patients with cancer [1] . During 1995, rapidly. Appropriate cultures and radiographic procedures are 15% of our neutropenic patients at the Greenebaum Cancer performed, and broad-spectrum antibiotic therapy is immediCenter (formerly the University of Maryland Cancer Center) ately initiated. were colonized with VRE. Because of the high prevalence of Empirical antibiotic regimens varied over the study period, but VRE colonization and the resistance of VRE to all bactericidal they included imipenem, ceftazidime, ciprofloxacin, and piperacilantibiotics, we sought to identify potentially alterable risk faclin. Acyclovir is the only antimicrobial agent used for chemotors for VRE bacteremia in cancer patients. We estimated the prophylaxis. One hundred percent of patients with VRE bacteremia (10 of 10) vs. 56% of patients without VRE bacteremia (23 of 41) defined as a neutrophil count of õ0.5 1 10 9 /L. C. difficile infection was defined as either a positive cytotoxicity assay or had acute leukemia (P Å .01, Fisher's exact test). The patients with VRE bacteremia were older (mean age, 62 vs. 53 years; a positive EIA for toxin (Cambridge Bioscience, Cambridge, MA) in conjunction with diarrhea ( §3 nonsolid bowel move-P Å .11). At the time of initial VRE colonization, those patients with VRE bacteremia were more likely to have had C. difficile ments a day). Antibiotic use was recorded, including number of days of therapy with intravenous and oral vancomycin, intrainfection (20% [2 of 10] vs. 3% [1 of 41] ; P Å .09) and had had more days of therapy with parenteral vancomycin (mean, venous and oral metronidazole, imipenem, ceftazidime, piperacillin, and intravenous ciprofloxacin, as well as the total number 10 vs. 8; P Å .14), oral vancomycin (mean, 6 vs. 3; P Å .09), and ceftazidime (mean, 7 vs. 3; P Å .10) within the last 90 of days of antibiotic therapy during the 90 days before the first positive surveillance culture and during the follow-up period.
days than had patients without VRE bacteremia. During the follow-up period, patients with VRE bacteremia Statistical analysis. All statistical analyses were performed with SAS statistical software (SAS Institute, Carey, NC). Conhad a higher rate of C. difficile infection (mean, 38 vs. 1 per 1,000 follow-up days; P Å .01) and had a higher rate of antitinuous variables were compared by Wilcoxon's rank-sum test, and categorical variables by Fisher's exact test or Pearson's biotic use, specifically of parenteral vancomycin (mean, 494 vs. 85 days per 1,000 follow-up days; P Å .02) and ciprofloxax 2 test. Cox's proportional hazards models were used to account for variations in follow-up while estimating the associacin (mean, 215 vs. 51 days per 1,000 follow-up days; P Å .04), than patients without VRE bacteremia. In addition, patients tion of C. difficile infection, vancomycin use, and total antibiotic use with VRE bacteremia in VRE-colonized patients.
with VRE bacteremia had a higher rate of neutropenia (mean, 574 vs. 191 days per 1,000 follow-up days; P Å .06) than C. difficile infection, vancomycin use, and total antibiotic use were modeled as time-dependent variables. It was assumed that patients without VRE bacteremia. Bacteremia with VRE in leukemia patients colonized with C. difficile infection increased the risk of bacteremia for a total of 14 days, 7 days before and after the positive C. difficile toxin VRE. Because VRE bacteremia occurred exclusively in VREcolonized patients with acute leukemia, factors such as antiassay. Two-sided P values of õ.05 were considered statistically significant; however, exact P values are reported.
biotic use could be associated with acute leukemia, not necessarily VRE bacteremia. For this reason, patients with acute leukemia were compared with regard to the presence or absence Results of subsequent VRE bacteremia (table 1) . C. difficile infection and antibiotic use (specifically of parenteral vancomycin) durOutcome of bacteremia with VRE in cancer patients. There were 10 cases of VRE bacteremia among 56 VRE-colonized ing colonization remained statistically significant risk factors. However, antibiotic use and C. difficile infection within the 90 patients during the study period. Ninety-four percent of the charts (51 of 56) were available for review. Sixty-five percent days prior to colonization were not significantly different. Because all VRE-colonized patients with VRE bacteremia of the VRE-colonized population (33 of 51) had acute leukemia, 19% (10) had other hematologic malignancies, 10% (5) had acute leukemia, only patients with acute leukemia were used to identify risk factors for infection, with use of Cox's had solid tumors, and 6% (3) had other nonmalignant conditions.
proportional hazards models to account for differences in follow-up times (table 2) . C. difficile infection was associated During the study 10 patients developed VRE bacteremia within 1 -326 days (1, 5, 10, 14, 15, 18, 19, 85, 117, and 326 with a statistically significant eightfold increase in the risk of VRE bacteremia in VRE-colonized patients with acute leukedays) of their first positive VRE rectal culture. The incidence rate of VRE bacteremia in VRE-colonized patients was 7.4 per mia. When adjusted for age, the risk was diminished but remained statistically significant. 10,000 patient follow-up days (10 bacteremias during 13,521 follow-up days), or 63 per 10,000 neutropenic follow-up days
The time relationships between the positive C. difficile tests and VRE bacteremia in the five patients with both are shown (10 bacteremias during 1,582 days of neutropenia). Although initial VRE colonization was detected during a period of neuin figure 1 . Patient 5 does not contribute to the cited risk ratio because the positive C. difficile test preceded the VRE tropenia, four of the 10 patients (40%) were not neutropenic at the time of VRE bacteremia.
bacteremia by ú7 days. Although vancomycin use and total antibiotic use increased the risk of VRE bacteremia, they were All four of the patients without neutropenia had only a single culture positive for VRE, and three of four defervesced without not statistically significant risk factors and were unaffected by / 9c3f$$no68 10-20-97 10:48:09 cida UC: CID patients with use of a cohort design. In our study and others days of follow-up, mean 574 230 .11 [1, 3, 4] , the majority of the risk among VRE-colonized cancer 
/ 9c3f$$no68
10-20-97 10:48:09 cida UC: CID cin, during follow-up. However, when adjustments were made Although this study included all of the VRE-colonized patients at our center over 3 years, it was a small study. C. difficile for different follow-up times, only C. difficile infection was infection was associated with VRE bacteremia in only 40% of significantly associated with VRE bacteremia. the patients. Other risk factors such as chemotherapy-induced The association between C. difficile infection and VRE bactermucositis probably contribute to the risk of VRE bacteremia emia may be causal but could also serve as a marker of increased in cancer patients. However, unlike mucositis, C. difficile infecmorbidity in patients with acute leukemia. Other factors associated tion is a potentially alterable risk factor, and if the association with increased morbidity, such as chemotherapy-induced mucosiis causal, preventing C. difficile infection could reduce the tis, may be responsible for the increased VRE bacteremia. Neverincidence of VRE bacteremia in patients with acute leukemia. theless, the association between C. difficile infection and VRE bacteremia is biologically plausible. Investigators of case series
